Get the Stockscreener App
0.00
100.00%
-10.15
After Hours:
10.17
10.17
+
Iteos Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.15
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$448.68M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
0.00
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.35
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
0.00 | 448.68M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
Can iTeos Therapeutics Inc. stock deliver surprise earnings beatJuly 2025 Setups & High Yield Equity Trading Tips - Newser
Why iTeos Therapeutics Inc. stock remains undervalued2025 Trading Recap & Reliable Price Breakout Signals - BỘ NỘI VỤ
Is KCD Industries India Limited One of the Top Picks for Growth Investors in YEARCandlestick Pattern Analysis & Consistent High Yield Stocks - earlytimes.in
Can Marco Cables Conductors Limited Generate Insider Confidence Through Shareholder ReturnsPrice Momentum Alerts & Free Realize Exceptional Returns - earlytimes.in
iTeos Therapeutics Inc Stock Analysis and ForecastBull Market Opportunities & Affordable Trading Growth - earlytimes.in
Is iTeos Therapeutics Inc. stock a dividend growth opportunityGap Down & Safe Entry Point Alerts - newser.com
Will iTeos Therapeutics Inc. stock sustain high P E ratiosJobs Report & Community Consensus Trade Signals - newser.com
Will iTeos Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Price Swings & Expert Verified Movement Alerts - newser.com
Will iTeos Therapeutics Inc. price bounce be sustainableWeekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Will iTeos Therapeutics Inc. see short term momentum2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Using RSI to spot recovery in iTeos Therapeutics Inc.Market Activity Recap & Precise Entry and Exit Recommendations - newser.com
Can iTeos Therapeutics Inc. stock sustain free cash flow growth - newser.com
Will iTeos Therapeutics Inc. stock continue upward momentumTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
Can iTeos Therapeutics Inc. stock maintain growth trajectory2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Predicting iTeos Therapeutics Inc. trend using moving averagesWeekly Trade Analysis & Risk Controlled Swing Alerts - newser.com
Forecasting iTeos Therapeutics Inc. price range with options dataTrade Volume Report & Smart Allocation Stock Reports - newser.com
Technical signs of recovery in iTeos Therapeutics Inc.2025 Momentum Check & Daily Price Action Insights - newser.com
How sustainable is iTeos Therapeutics Inc. stock dividend payoutQuarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com
Is a relief rally coming for iTeos Therapeutics Inc. holders2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
Is iTeos Therapeutics Inc. forming a bottoming baseJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
Applying big data sentiment scoring on iTeos Therapeutics Inc.Earnings Summary Report & Capital Efficient Trading Techniques - newser.com
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):